Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Control Form 3 Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Random Nicotine Delivery on Smoking Cessation

NCT03674970
View directory record Official record
Conditions
Smoking Cessation, Cigarette Smoking, Smoking (Tobacco) Addiction
Interventions
Nicotine Film
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults

NCT01260727
View directory record Official record
Conditions
HIV Infections
Interventions
PENNVAX-G DNA Vaccine, MVA-CMDR Vaccine, Placebo PENNVAX-G Vaccine, Placebo MVA-CMDR Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron Supplementation and Side Effects

NCT04018300
View directory record Official record
Conditions
Iron Deficiency Anemia, Iron Overload
Interventions
Ferrous sulfate, Aspiron, Placebo
Dietary Supplement · Other
Lead sponsor
Iowa State University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

NCT02004691
View directory record Official record
Conditions
Sphingomyelin Lipidosis
Interventions
placebo (saline), Olipudase alfa
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
3
States / cities
San Francisco, California • Decatur, Georgia • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A New Paradigm for Vitamin D Sufficiency

NCT02969850
View directory record Official record
Conditions
New Biomarkers for Measuring Vitamin D Level
Interventions
Vitamin D Supplementation, Placebo, Calcium
Dietary Supplement · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

NCT00487942
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
12
States / cities
Garden Grove, California • National City, California • Paramount, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 4, 2026, 9:36 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

NCT00772525
View directory record Official record
Conditions
Multiple Sclerosis, Optic Nerve, Neuritis
Interventions
Nerispirdine, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Sep 4, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional Results available

Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women

NCT03165747
View directory record Official record
Conditions
Menopausal Osteoporosis
Interventions
VSL#3, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 4 Interventional

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome

NCT00610610
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 4, 2026, 9:36 PM EDT
Not yet recruiting Not applicable Interventional

Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women

NCT07406243
View directory record Official record
Conditions
Aging, Postmenopause
Interventions
Mitoquinone (MitoQ), Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
60 Years and older · Female only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

NCT06637631
View directory record Official record
Conditions
Crohn's Disease
Interventions
SAR441566, SAR441566 matching Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Sun City, Arizona • Bristol, Connecticut • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Triple Therapy in T1DM

NCT03899402
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT02466425
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Dothan, Alabama • Orange, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 4, 2026, 9:36 PM EDT
Withdrawn Phase 2 Interventional

The Effectiveness of Lower Cyclosporine Doses for Psoriasis

NCT00377325
View directory record Official record
Conditions
Psoriasis
Interventions
Cyclosporine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Energy™: A Study Assessing the Impact of Health and Wellness Products on Fatigue

NCT07026448
View directory record Official record
Conditions
Fatigue
Interventions
Energy Placebo Control, Energy Active Product 1, Energy Active Product 2, Energy Active Product 3
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Tolebrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 4, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

NCT04411641
View directory record Official record
Conditions
Non-relapsing Secondary Progressive Multiple Sclerosis
Interventions
Tolebrutinib, Placebo to match Tolebrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Phoenix, Arizona • Arcadia, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 4, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old

NCT07049159
View directory record Official record
Conditions
Shigella
Interventions
ShigETEC vaccine, Placebo, Challenge: Shigella flexneri 2457T at a dose of 1.5x10^3 CFU
Biological · Other
Lead sponsor
Eveliqure Biotechnologies GmbH
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2025 · Synced Sep 4, 2026, 9:36 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Ramipril for the Treatment of Oligospermia

NCT01856361
View directory record Official record
Conditions
Oligospermia, Teratospermia, Asthenozoospermia, Male Infertility
Interventions
Ramipril, Placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 4, 2026, 9:36 PM EDT